ICICI Direct has given Buy recommendation for Laurus Labs with a target price of Rs. 690 in its research report issued on Apr 30, 2022

ICICI Direct’s research report on Laurus Labs

Laurus Labs operates in the segment of generic APIs & FDFs (formulations), custom synthesis and biotechnology. Major focus in APIs is on ARV, oncology and other APIs. It has 11 manufacturing units (six FDA approved sites) with 73 DMFs, 31 ANDAs filed (15 Para IV, 10 first to file) and 184 patents granted • Laurus acquired Richore Life Sciences to diversify in area of recombinant animal origin free products, enzymes as well as building biologics CDMO.

Outlook

We continue to remain positive and retain our BUY rating on the stock. Valued at Rs 690 i.e. 26x P/E on FY24E EPS of Rs 26.5.

Leave a Reply

Your email address will not be published.